These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3089179)

  • 1. Hepatitis B virus infection in multitransfused haemophiliacs.
    Nebbia G; Moroni GA; Simoni L; Belli M; Carnelli V
    Arch Dis Child; 1986 Jun; 61(6):580-4. PubMed ID: 3089179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions between hepatotropic viruses in patients with haemophilia.
    Lee CA; Kernoff PB; Karayiannis P; Farci P; Thomas HC
    J Hepatol; 1985; 1(4):379-84. PubMed ID: 3932510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virus safety of pasteurized factor VIII and factor IX concentrates: study in virgin patients.
    Heimburger N; Karges HE; Weidmann E
    Dev Biol Stand; 1987; 67():303-10. PubMed ID: 3038638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Change in immune response to hepatitis B in boys with haemophilia.
    Williams MD; Boxall EH; Hill FG
    J Med Virol; 1988 Jul; 25(3):317-27. PubMed ID: 3139829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of hepatitis B and C seromarkers and abnormal liver function tests among hemophiliacs in Guilan (northern province of Iran).
    Mansour-Ghanaei F; Fallah MS; Shafaghi A; Yousefi-Mashhoor M; Ramezani N; Farzaneh F; Nassiri R
    Med Sci Monit; 2002 Dec; 8(12):CR797-800. PubMed ID: 12503038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy in viral inactivation of the concentrates of factor VIII and IX by the solvent/detergent procedure. Evaluation in patients with hemophilia].
    Guerois C; Parquet A; Vicariot M; Lecoeur FF; Maisonneuve P; Courouce AM; Dubois F; Laurian Y
    Presse Med; 1991 Jun; 20(25):1163-6. PubMed ID: 1830653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of infection with hepatitis B virus in 56 patients with haemophilia A 1971-1979.
    Stirling ML; Murray JA; Mackay P; Black SH; Peutherer JF; Ludlam CA
    J Clin Pathol; 1983 May; 36(5):577-80. PubMed ID: 6404950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of several second generation serological assays to determine the true prevalence of hepatitis C virus infection in haemophiliacs treated with non-virus inactivated factor VIII and IX concentrates.
    Watson HG; Ludlam CA; Rebus S; Zhang LQ; Peutherer JF; Simmonds P
    Br J Haematol; 1992 Apr; 80(4):514-8. PubMed ID: 1581236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy-induced hepatitis risk in hemophilia patients].
    Schiller WG; Renger FG
    Z Arztl Fortbild (Jena); 1983; 77(19):807-10. PubMed ID: 6417919
    [No Abstract]   [Full Text] [Related]  

  • 10. Chronic hepatitis in childhood: the spectrum of the disease.
    Bortolotti F; Calzia R; Vegnente A; Cadrobbi P; Rugge M; Armigliato M; Marazzi MG; Iorio R; Crivellaro C; Piscopo R
    Gut; 1988 May; 29(5):659-64. PubMed ID: 3396953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transmissibility of human immunodeficiency virus in haemophilic and non-haemophilic children living in a private school in France.
    Berthier A; Chamaret S; Fauchet R; Fonlupt J; Genetet N; Gueguen M; Pommereuil M; Ruffault A; Montagnier L
    Lancet; 1986 Sep; 2(8507):598-601. PubMed ID: 2875320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commercial factor VIII associated hepatitis, 1974-75, in the United Kingdom: a retrospective survey.
    Craske J; Kirk P; Cohen B; Vandervelde EM
    J Hyg (Lond); 1978 Jun; 80(3):327-36. PubMed ID: 649945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver dysfunction in Pennsylvania's multitransfused hemophiliacs.
    Hasiba U; Eyster ME; Gill FM; Kajani M; Lewis JH; Lusch CJ; Prager D; Rice SA; Shapiro SS
    Dig Dis Sci; 1980 Oct; 25(10):776-82. PubMed ID: 6775916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral safety of plasma-derived factor VIII and IX concentrates.
    Ludlam CA
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Viral hepatitis in hemophiliac patients treated with commercial concentrates of factors VIII and IX].
    Miranda ML; Lissen E; Vinuesa M; Jiménez JM; García de Pesquera F; Leal M
    Med Clin (Barc); 1985 Apr; 84(13):516-9. PubMed ID: 3923278
    [No Abstract]   [Full Text] [Related]  

  • 16. Virucidal treatment of clotting factor concentrates.
    Mannucci PM; Colombo M
    Lancet; 1988 Oct; 2(8614):782-5. PubMed ID: 2901620
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk factors for infection with HBV and HCV in a largecohort of hemophiliac males.
    Soucie JM; Richardson LC; Evatt BL; Linden JV; Ewenstein BM; Stein SF; Leissinger C; Manco-Johnson M; Sexauer CL;
    Transfusion; 2001 Mar; 41(3):338-43. PubMed ID: 11274587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies to hepatitic C virus and chronic liver disease among Finnish patients with haemophilia.
    Ebeling F; Rasi V; Naukkarinen R; Leikola J
    Ann Med; 1990 Dec; 22(6):393-6. PubMed ID: 1963789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C and pasteurised factor VIII and IX concentrates.
    Klarmann D; Kreuz W; Auerswald G; Auberger K; Rabenau H; Gürtler L; Roggendorf M
    Thromb Haemost; 1995 Apr; 73(4):736-7. PubMed ID: 7495095
    [No Abstract]   [Full Text] [Related]  

  • 20. [HTLV-III antibodies and immunologic changes in hemophilic children. Prevalence of HTLV-III antibodies in hemophilic children and their relatives living in the same household].
    Zenz W; Muntean W; Teubl I; Beaufort F; Heinz FX
    Padiatr Padol; 1987; 22(1):33-41. PubMed ID: 3108827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.